C07K14/4717

ACIDIC BETA-LACTOGLOBULIN BEVERAGE PREPARATION

The present invention pertains to a new packaged, heat-treated beverage preparation having a pH in the range of 2.0-4.7. The invention furthermore relates to a method of producing a packaged, heat-treated beverage preparation and to different uses of the packaged, heat-treated beverage preparation.

METHODS OF PROTEIN PURIFICATION
20220098234 · 2022-03-31 ·

Provided herein are methods for purifying proteins from mixtures of proteins using ultrafiltration, such as tangential-flow filtration (TFF). Provided herein are methods for isolating an apoprotein from a protein solution comprising a conjugated protein, wherein the conjugated protein comprises the apoprotein and a hydrophobic ligand associated with the apoprotein.

PEPTIDE AND USE THEREOF

Peptides consisting of the amino acid sequence of any of LIVTQTMKGL (SEQ ID NO: 1), LIVTQTMKG (SEQ ID NO: 2), LIVTQTMK (SEQ ID NO: 3), IVTQTMKGL (SEQ ID NO: 4), IVTQTMKG (SEQ ID NO: 5), and VTQTMKGL (SEQ ID NO: 6) are useful for improving intestinal barrier function, for suppressing blood glucose elevation, for improving insulin sensitivity, for promoting FGF21 secretion, for suppressing stress or protecting nerves, or for reducing fatigue.

RECOMBINANT MILK PROTEINS
20220098259 · 2022-03-31 ·

Provided herein are compositions and methods for producing recombinant milk proteins, as well as food compositions comprising the same. In aspects, the recombinant milk proteins of the disclosure are recombinant fusion proteins comprising casein and beta-lactoglobulin.

RECOMBINANT FUSION PROTEINS FOR PRODUCING MILK PROTEINS IN PLANTS
20220098608 · 2022-03-31 ·

Provided herein are compositions and methods for producing milk proteins in plants, which allow for safe, sustainable and humane production of milk proteins for commercial use, such as use in food compositions. The disclosure provides recombinant fusion proteins comprising a milk protein, or fragment thereof and a structured mammalian, avian, plant, or fungal protein, or fragment thereof. The disclosure also provides methods for producing the recombinant fusions proteins, and food compositions comprising the same.

Identification of transglutaminase substrates and uses therefor

According to one aspect, the present disclosure provides a method of identifying a substrate of a transglutaminase using a peptide array comprising a plurality of peptides. The method includes the steps of contacting the peptides in the peptide array with the transglutaminase, allowing the transglutaminase to bind to the peptides, and identifying the substrate of the transglutaminase.

RECOMBINANT COMPONENTS AND COMPOSITIONS FOR USE IN FOOD PRODUCTS

Provided are methods for producing food products comprising recombinant components, and compositions used in and food products produced by such methods.

Recombinant milk proteins
11142555 · 2021-10-12 · ·

Provided herein are compositions and methods for producing recombinant milk proteins, as well as food compositions comprising the same. In aspects, the recombinant milk proteins of the disclosure are recombinant fusion proteins comprising casein and beta-lactoglobulin.

Compositions and methods for treating hemoglobinopathies

The present invention features compositions and methods for editing deleterious mutations associated with hemoglobinopathies, such as sickle cell disease (SCD). In particular embodiments, the invention provides methods for correcting mutations in a beta globin polynucleotide using modified adenosine base editors termed “ABE8” having unprecedented levels (e.g., >60-70%) of efficiency.

SYNTHESIS AND STRUCTURE OF HIGH POTENCY RNA THERAPEUTICS

This invention provides expressible polynucleotides, which can express a target protein or polypeptide. Synthetic mRNA constructs for producing a protein or polypeptide can contain one or more 5′ UTRs, where a 5′ UTR may be expressed by a gene of a plant. In some embodiments, a 5′ UTR may be expressed by a gene of a member of Arabidopsis genus. The synthetic mRNA constructs can be used as pharmaceutical agents for expressing a target protein or polypeptide in vivo.